Neuralink, the neurotechnology company co-founded by Tesla (NASDAQ:TSLA) CEO Elon Musk, said on Thursday it will launch a clinical study in Great Britain to test how its chips can help patients with severe paralysis to control digital and physical tools with their thoughts.
The company is partnering with the University College London Hospitals Trust and Newcastle Hospitals to conduct the study, it said in a post on X.
According to Neuralink, patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study.
Musk, who also leads internet service provider Starlink (STRLK) and space exploration company SpaceX (SPACE), previously said that Neuralink aims to implant Blindsight in a human for the first time later this year.
